Table 4. Antibiotic susceptibility pattern of Gram-negative isolates in HBV-ACLF patients with infection.
| S/I/R | Antibiotic discs tested (n = 127) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CAZ n (%) | CTX n (%) | F n (%) | IPM n (%) | LEV n (%) | PRL n (%) | SCF n (%) | SXT n (%) | TGC n (%) | TZP n (%) | |
| S I R | 78 (61.42) 9 (7.09) 40 (31.5) | 46 (36.22) 6 (4.72) 75 (59.06) | 88 (69.29) 16 (12.6) 23 (18.11) | 114 (89.76) 5 (3.94) 8 (6.3) | 61 (48.03) 3 (2.36) 63 (49.61) | 32 (25.2) 12 (9.45) 83 (65.35) | 82 (64.57) 27 (21.26) 18 (14.17) | 57 (44.88) 4 (3.15) 66 (51.97) | 103 (81.1) 17 (13.39) 7 (5.51) | 99 (77.95) 18 (14.17) 10 (7.87) |
Note:
CAZ, Ceftazidime; CTX, Cefotaxime; F, Nitrofurantoin; IPM, Imipenem; LEV, Levofloxacin; PRL, Piperacillin; SCF, Cefoperazone/sulbactam; SXT, Sulfamethoxazole and trimethoprim; TGC, Tigecycline; TZP, Piperacillin/tazobactam; S, sensitive; I, intermediate; R, resistant.